

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM494216

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Mission Pharmacal Company		05/30/2018	Corporation: TEXAS
RECEIVING PARTY DATA			
Name:	MainPointe Pharmaceuticals, LLC		
Street Address:	333 East Main Street #200		
City:	Louisville		
State/Country:	KENTUCKY		
Postal Code:	40202		
Entity Type:	Corporation: KENTUCKY		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87428692	LOSE THE LICE	
CORRESPONDENCE DATA			
Fax Number:	6123393061		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	5124926413		
Email:	tmg@slwip.com		
Correspondent Name:	Pamela B. Huff		
Address Line 1:	P.O. Box 2938		
Address Line 2:	Schwegman Lundberg & Woessner P.A.		
Address Line 4:	Minneapolis, MINNESOTA 55402		
ATTORNEY DOCKET NUMBER:	4825.000008		
NAME OF SUBMITTER:	Pamela B. Huff		
SIGNATURE:	/pbhuff35901/		
DATE SIGNED:	10/16/2018		
Total Attachments: 2			
source=DRS and Lycelle trademark assignment#page1.tif			
source=DRS and Lycelle trademark assignment#page2.tif			

CH \$40.00 87428692

ASSIGNMENT

WHEREAS, MISSION PHARMACAL COMPANY ("Assignor"), a Texas corporation having its principal place of business at 10999 IH-10 West, Suite 1000, San Antonio, Texas 78230 USA, owns all right, title, and interest in and to the trademarks shown on Exhibit A (the "Marks");


WHEREAS, MAINPOINTE PHARMACEUTICALS, LLC ("Assignee"), a Kentucky limited liability company having its principal place of business at 333 East Main Street, #200, Louisville, Kentucky 40202, desires to acquire all right, title, and interest in and to said Marks, the goodwill of the business symbolized thereto, and the underlying business associated therewith;

WHEREAS, pursuant to the terms of the Asset Purchase Agreement dated as of January 16, 2018 (the "Asset Purchase Agreement"), Assignor has agreed to convey, transfer, and assign to Assignee, among other assets, the Purchased IP (as that term is defined in the Asset Purchase Agreement), and has agreed to execute and deliver this Assignment.

NOW, THEREFORE, in consideration for the execution of the Asset Purchase Agreement, the payment of the consideration stipulated in the Asset Purchase Agreement and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer, and convey to Assignee all of its right, title, and interest in and to said Marks, all rights derived from or associated with use of the Marks by Assignor, together with the goodwill of the business symbolized thereto and the underlying business associated therewith, and the right to recover for past infringement of said Marks. Assignor represents and warrants that it has not previously assigned, licensed, or conveyed any interest in said Marks or the other rights referenced herein, and Assignor agrees to execute any further lawful documents needed to give full force and effect to this instrument.

Executed this 30th day of May 2018


Mission Pharmacal Company, a Texas corporation ("Assignor")

By: 

Name: Thomas J. Dooley

Title: Chief Financial Officer

MainPointe Pharmaceuticals, LLC, a Kentucky limited liability company ("Assignee")

By: 

Name: Douglas E. Morris

Title: Chief Financial Officer

EXHIBIT A

TRADEMARK	COUNTRY	STATUS	APP NUMBER	REG NUMBER
DR SMITH'S & DESIGN (Class 5)	Canada	Registered	1680176	TMA971556
DR SMITH'S & DESIGN (Class 5)	European Union	Registered	012125498	012125498
LOSE THE LICE (Class 5)	United States	Allowed	87/428,692	